Novel TKI-resistant BCR-ABL1 gatekeeper residue mutations retain in vitro sensitivity to axitinib

Leukemia. 2016 Jun;30(6):1405-9. doi: 10.1038/leu.2015.303. Epub 2015 Oct 29.

E A Lasater¹, E S Massi¹, A Stecula², J Politi¹, S K Tan¹, C C Smith¹, M Gunthorpe³, J P Holmes⁴, F Chehab³, A Sali^{2

5

6}, N P Shah^{1

7}

¹ Division of Hematology/Oncology, University of California, San Francisco, CA, USA.
² Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, USA.
³ Department of Laboratory Medicine, University of California, San Francisco, CA, USA.
⁴ Annadel Medical Group, Santa Rosa, CA, USA.
⁵ Department of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA.
⁶ California Institute for Quantitative Biosciences, University of California, San Francisco, CA, USA.
⁷ Helen Diller Comprehensive Cancer Center, University of California, San Francisco, CA, USA.

No abstract available

Publication types